Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Recruiting · NCT07414043 · Observational (researchers observe without assigning treatment) · Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
View the official record on ClinicalTrials.gov →What this trial is about
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved
Who can take part
Age range
12 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 12 years
- Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®)
Exclusion criteria
- Type 1 and type 2 diabetes mellitus
- \- Secondary forms of obesity:
- Hypothalamic obesity (both monogenic and acquired forms);
- Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.);
- Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism)
Where it is running
1 location listed.
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Bologna, Bologna, Italy